Genix Pharmaceuticals Corporation
GENPF
$0.0138
-$0.0262-65.50%
OTC PK
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.82% | -52.46% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.79% | -88.00% | |||
| Operating Income | -2.79% | 87.99% | |||
| Income Before Tax | 51.52% | -166.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.52% | -166.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.52% | -166.93% | |||
| EBIT | -2.79% | 87.99% | |||
| EBITDA | -2.82% | 73.04% | |||
| EPS Basic | 53.85% | -168.42% | |||
| Normalized Basic EPS | 50.00% | 68.00% | |||
| EPS Diluted | 53.85% | -168.42% | |||
| Normalized Diluted EPS | 50.00% | 68.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||